Condition
Essential Hypertension With Stable Angina and Dyslipidemia
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Azilsartan
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
100%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 4 (1)
Trial Status
Withdrawn1